[1]
|
Dörk T, Hillemanns P, Tempfer C, et al. Genetic Susceptibility to Endometrial Cancer:Risk Factors and Clinical Management[J]. Cancers (Basel),2020,12:2407. |
[2]
|
Zhao S, Chen L, Zang Y, et al. Endometrial cancer in Lynch syndrome[J]. Int J Cancer,2022,150:7-17. |
[3]
|
Pastor DM, Schlom J. Immunology of Lynch Syndrome[J]. Curr Oncol Rep, 2021,23:96. |
[4]
|
Poulogiannis G, Frayling IM, Arends MJ. DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch syndrome[J]. Histopathology,2010,56:167-179. |
[5]
|
Kempers MJ, Kuiper RP, Ockeloen CW, et al. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome:a cohort study[J]. Lancet Oncol,2011,12:49-55. |
[6]
|
Morak M, Ibisler A, Keller G, et al. Comprehensive analysis of the MLH1 promoter region in 480 patients with colorectal cancer and 1150 controls reveals new variants including one with a heritable constitutional MLH1 epimutation[J]. J Med Genet, 2018,55:240-248. |
[7]
|
Dominguez-Valentin M, Sampson JR, Seppälä TT, et al. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants:findings from the Prospective Lynch Syndrome Database[J]. Genet Med,2020,22:15-25. |
[8]
|
Ryan NAJ, Morris J, Green K, et al. Association of Mismatch Repair Mutation With Age at Cancer Onset in Lynch Syndrome:Implications for Stratified Surveillance Strategies[J]. JAMA Oncol,2017,3:1702-1706. |
[9]
|
Staff S, Aaltonen M, Huhtala H, et al. Endometrial cancer risk factors among Lynch syndrome women:a retrospective cohort study[J]. Br J Cancer, 2016, 115:375-381. |
[10]
|
Broaddus RR, Lynch HT, Chen LM, et al. Pathologic features of endometrial carcinoma associated with HNPCC:a comparison with sporadic endometrial carcinoma[J]. Cancer,2006,106:87-94. |
[11]
|
Rossi L, Le Frere-Belda MA, Laurent-Puig P, et al. Clinicopathologic Characteristics of Endometrial Cancer in Lynch Syndrome:A French Multicenter Study[J]. Int J Gynecol Cancer,2017,27:953-960. |
[12]
|
Ramchander NC, Ryan NAJ, Walker TDJ,et al. Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer[J]. Front Immunol,2020,10:3023. |
[13]
|
Bogani G, Tibiletti MG, Ricci MT, et al. Lynch syndrome-related non-endometrioid endometrial cancer:analysis of outcomes[J]. Int J Gynecol Cancer,2020,30:56-61. |
[14]
|
Carr C, Son J, Yao M, et al. Clinicopathologic characteristics and outcomes of endometrial Cancer patients with mismatch repair deficiency in the era of universal Lynch syndrome screening[J]. Gynecol Oncol,2020,159:712-720. |
[15]
|
杨子慧,刘新宇,杨曦,等.林奇综合征患者子宫内膜癌及卵巢癌的筛查与预防[J].国际妇产科学杂志,2021,48:453-456. Yang ZH, Liu XY, Yang X, et al. Screening and prevention of endometrial carcinoma and ovarian cancer in patients with Lynch syndrome[J]. Guoji Fuchanke Zazhi,2021
,48:453-456. |
[16]
|
Raevaara TE, Korhonen MK, Lohi H, et al. Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1[J]. Gastroenterology, 2005,129:537-549. |
[17]
|
Leclerc J, Vermaut C, Buisine MP. Diagnosis of Lynch Syndrome and Strategies to Distinguish Lynch-Related Tumors from Sporadic MSI/dMMR Tumors[J]. Cancers (Basel),2021,13:467. |
[18]
|
Dietmaier W, Wallinger S, Bocker T, et al. Diagnostic microsatellite instability:definition and correlation with mismatch repair protein expression[J]. Cancer Res,1997,57:4749-56. |
[19]
|
Houlleberghs H, Dekker M, Lusseveld J, et al. Three-step site-directed mutagenesis screen identifies pathogenic MLH1 variants associated with Lynch syndrome[J]. J Med Genet,2020,57:308-315. |
[20]
|
Gallon R, Gawthorpe P, Phelps RL, et al. How Should We Test for Lynch Syndrome? A Review of Current Guidelines and Future Strategies[J]. Cancers (Basel),2021,13:406. |
[21]
|
Lu KH, Broaddus RR. Endometrial Cancer[J]. N Engl J Med, 2020, 383:2053-2064. |
[22]
|
Van den Heerik ASVM, Horeweg N, De Boer SM, et al. Adjuvant therapy for endometrial cancer in the era of molecular classification:radiotherapy, chemoradiation and novel targets for therapy[J]. Int J Gynecol Cancer,2021,31:594-604. |
[23]
|
Gompel A. Progesterone and endometrial cancer[J]. Best Pract Res Clin Obstet Gynaecol,2020,69:95-107. |
[24]
|
Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency[J]. N Engl J Med,2015,372:2509-2520. |
[25]
|
Marabelle A, Le DT, Ascierto PA, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer:Results From the Phase II KEYNOTE-158 Study[J]. J Clin Oncol,2020,38:1-10. |
[26]
|
Burn J, Sheth H, Elliott F, et al. Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study:a double-blind, randomised, placebo-controlled trial[J]. Lancet,2020,395:1855-1863. |
[27]
|
Seppälä TT, Dominguez-Valentin M, Crosbie EJ, et al. Uptake of hysterectomy and bilateral salpingo-oophorectomy in carriers of pathogenic mismatch repair variants:a Prospective Lynch Syndrome Database report[J]. Eur J Cancer,2021,148:124-133. |
[28]
|
Crosbie EJ, Ryan NAJ, Arends MJ, et al. Manchester International Consensus Group, Evans DG. The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome[J]. Genet Med,2019,21:2390-2400. |
[29]
|
Roudko V, Cimen Bozkus C, Greenbaum B, et al. Lynch Syndrome and MSI-H Cancers:From Mechanisms to "Off-The-Shelf" Cancer Vaccines[J]. Front Immunol,2021,12:757804. |
[30]
|
Bayó C, Jung G, Español-Rego M, et al. Vaccines for Non-Viral Cancer Prevention[J]. Int J Mol Sci,2021,22:10900. |